NVOS vs. AKTX, ATHE, TBIO, ONVO, ELAB, OTRK, BCDA, AEZS, IKT, and MBRX
Should you be buying Novo Integrated Sciences stock or one of its competitors? The main competitors of Novo Integrated Sciences include Akari Therapeutics (AKTX), Alterity Therapeutics (ATHE), Telesis Bio (TBIO), Organovo (ONVO), Elevai Labs (ELAB), Ontrak (OTRK), BioCardia (BCDA), Aeterna Zentaris (AEZS), Inhibikase Therapeutics (IKT), and Moleculin Biotech (MBRX). These companies are all part of the "medical" sector.
Akari Therapeutics (NASDAQ:AKTX) and Novo Integrated Sciences (NASDAQ:NVOS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.
Akari Therapeutics has a net margin of 0.00% compared to Akari Therapeutics' net margin of -88.48%. Novo Integrated Sciences' return on equity of 0.00% beat Akari Therapeutics' return on equity.
Akari Therapeutics received 262 more outperform votes than Novo Integrated Sciences when rated by MarketBeat users.
5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Novo Integrated Sciences shares are owned by institutional investors. 61.8% of Akari Therapeutics shares are owned by company insiders. Comparatively, 10.9% of Novo Integrated Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Akari Therapeutics has higher earnings, but lower revenue than Novo Integrated Sciences.
In the previous week, Akari Therapeutics had 1 more articles in the media than Novo Integrated Sciences. MarketBeat recorded 1 mentions for Akari Therapeutics and 0 mentions for Novo Integrated Sciences. Novo Integrated Sciences' average media sentiment score of 0.00 equaled Akari Therapeutics'average media sentiment score.
Akari Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Novo Integrated Sciences has a beta of -1.78, meaning that its share price is 278% less volatile than the S&P 500.
Summary
Akari Therapeutics beats Novo Integrated Sciences on 8 of the 10 factors compared between the two stocks.
Get Novo Integrated Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Novo Integrated Sciences Competitors List
Related Companies and Tools
